Virtu Financial LLC decreased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 38.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,465 shares of the medical equipment provider's stock after selling 9,091 shares during the quarter. Virtu Financial LLC's holdings in Zimmer Biomet were worth $1,561,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. BLB&B Advisors LLC raised its holdings in Zimmer Biomet by 2.1% in the third quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider's stock valued at $529,000 after acquiring an additional 100 shares in the last quarter. FWG Holdings LLC increased its position in shares of Zimmer Biomet by 2.9% in the 3rd quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider's stock valued at $372,000 after purchasing an additional 101 shares during the last quarter. Financial Advocates Investment Management raised its holdings in shares of Zimmer Biomet by 3.5% in the 3rd quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider's stock valued at $330,000 after purchasing an additional 103 shares in the last quarter. M&R Capital Management Inc. grew its stake in shares of Zimmer Biomet by 14.1% during the third quarter. M&R Capital Management Inc. now owns 852 shares of the medical equipment provider's stock worth $92,000 after purchasing an additional 105 shares in the last quarter. Finally, Mill Creek Capital Advisors LLC increased its holdings in Zimmer Biomet by 5.1% in the second quarter. Mill Creek Capital Advisors LLC now owns 2,195 shares of the medical equipment provider's stock valued at $238,000 after buying an additional 106 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.
Zimmer Biomet Stock Performance
NYSE:ZBH traded down $0.10 during midday trading on Friday, reaching $106.74. The stock had a trading volume of 1,186,438 shares, compared to its average volume of 1,485,392. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The stock has a market cap of $21.25 billion, a P/E ratio of 20.31, a P/E/G ratio of 1.96 and a beta of 1.02. The firm has a fifty day simple moving average of $107.65 and a two-hundred day simple moving average of $108.82. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90.
Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting the consensus estimate of $1.74. The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business's quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.65 earnings per share. On average, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.
Analyst Ratings Changes
A number of analysts have issued reports on ZBH shares. Truist Financial lifted their price target on Zimmer Biomet from $112.00 to $117.00 and gave the stock a "hold" rating in a report on Friday, November 1st. JPMorgan Chase & Co. lowered their price target on Zimmer Biomet from $125.00 to $120.00 and set a "neutral" rating for the company in a report on Monday, September 16th. Canaccord Genuity Group cut their price objective on shares of Zimmer Biomet from $120.00 to $115.00 and set a "hold" rating on the stock in a report on Tuesday, September 10th. BTIG Research lowered their target price on shares of Zimmer Biomet from $134.00 to $126.00 and set a "buy" rating for the company in a report on Thursday, October 3rd. Finally, Wolfe Research started coverage on shares of Zimmer Biomet in a research note on Tuesday, September 10th. They set a "peer perform" rating on the stock. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Zimmer Biomet currently has a consensus rating of "Hold" and a consensus price target of $122.83.
Check Out Our Latest Research Report on Zimmer Biomet
Zimmer Biomet Profile
(
Free Report)
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
Read More
Before you consider Zimmer Biomet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.
While Zimmer Biomet currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
